ChromaDex Past Earnings Performance
Past criteria checks 0/6
ChromaDex has been growing earnings at an average annual rate of 22.1%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 16.3% per year.
Key information
22.1%
Earnings growth rate
27.4%
EPS growth rate
Life Sciences Industry Growth | 26.8% |
Revenue growth rate | 16.3% |
Return on equity | -17.4% |
Net Margin | -5.9% |
Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How ChromaDex makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 84 | -5 | 51 | 5 |
30 Sep 23 | 83 | -6 | 52 | 5 |
30 Jun 23 | 81 | -6 | 52 | 5 |
31 Mar 23 | 77 | -11 | 54 | 5 |
31 Dec 22 | 72 | -17 | 57 | 5 |
30 Sep 22 | 69 | -20 | 60 | 5 |
30 Jun 22 | 69 | -28 | 66 | 4 |
31 Mar 22 | 70 | -27 | 66 | 4 |
31 Dec 21 | 67 | -27 | 65 | 4 |
30 Sep 21 | 65 | -28 | 65 | 4 |
30 Jun 21 | 62 | -23 | 59 | 4 |
31 Mar 21 | 60 | -21 | 55 | 3 |
31 Dec 20 | 59 | -20 | 52 | 3 |
30 Sep 20 | 57 | -23 | 51 | 4 |
30 Jun 20 | 55 | -26 | 52 | 4 |
31 Mar 20 | 51 | -30 | 52 | 4 |
31 Dec 19 | 46 | -32 | 53 | 4 |
30 Sep 19 | 42 | -32 | 49 | 5 |
30 Jun 19 | 38 | -33 | 48 | 5 |
31 Mar 19 | 35 | -33 | 46 | 5 |
31 Dec 18 | 32 | -33 | 44 | 5 |
30 Sep 18 | 30 | -34 | 43 | 6 |
30 Jun 18 | 28 | -29 | 37 | 5 |
31 Mar 18 | 24 | -23 | 29 | 5 |
30 Dec 17 | 21 | -17 | 22 | 4 |
30 Sep 17 | 18 | -10 | 14 | 3 |
01 Jul 17 | 16 | -8 | 11 | 3 |
01 Apr 17 | 18 | -6 | 11 | 3 |
31 Dec 16 | 22 | -4 | 11 | 3 |
01 Oct 16 | 22 | -3 | 10 | 2 |
02 Jul 16 | 24 | -2 | 10 | 2 |
02 Apr 16 | 24 | -1 | 10 | 1 |
02 Jan 16 | 18 | -3 | 9 | 1 |
03 Oct 15 | 22 | -3 | 9 | 1 |
04 Jul 15 | 20 | -3 | 9 | 1 |
04 Apr 15 | 18 | -5 | 10 | 1 |
03 Jan 15 | 15 | -5 | 10 | 1 |
27 Sep 14 | 13 | -5 | 10 | 0 |
28 Jun 14 | 12 | -5 | 9 | 0 |
29 Mar 14 | 11 | -5 | 8 | 0 |
28 Dec 13 | 10 | -4 | 7 | 0 |
28 Sep 13 | 11 | -5 | 9 | 0 |
29 Jun 13 | 12 | -6 | 9 | 0 |
Quality Earnings: OCD1 is currently unprofitable.
Growing Profit Margin: OCD1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OCD1 is unprofitable, but has reduced losses over the past 5 years at a rate of 22.1% per year.
Accelerating Growth: Unable to compare OCD1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OCD1 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (6.5%).
Return on Equity
High ROE: OCD1 has a negative Return on Equity (-17.35%), as it is currently unprofitable.